
You must be at least 21 years old to access this website.
Our Products are for research and/or investigative purposes and are not suitable for direct human consumption or consumers, nor are they intended for clinical or therapeutic use. The statements and products listed on this website are not intended to diagnose, treat, cure, or prevent any disease. As such, they have not been evaluated or approved by the Federal Food and Drug Administration (the “FDA”). We are not a compounding pharmacy or outsourcing facility as defined under either Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Your cart is empty
Add compounds to get started
Research Comparison
Tirzepatide and GLP-3RT are both synthetic incretin-receptor peptides, differing in how many receptors they engage. Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, while GLP-3RT is a triple agonist that adds glucagon-receptor (GCGR) activity. Both are studied in vitro for incretin receptor pharmacodynamics and downstream cAMP signaling.
| Attribute | Tirzepatide | GLP-3RT |
|---|---|---|
| Receptor targets | GIP + GLP-1 | GLP-1 + GIP + GCGR |
| Agonist type | Dual incretin agonist | Triple agonist |
| Distinguishing mechanism | Dual-incretin activation | Adds glucagon-receptor (GCGR) activity |
| Research focus | Dual-incretin signaling, glucose metabolism | Multi-receptor pharmacodynamics |
Tirzepatide engages two incretin receptors (GIP and GLP-1), while GLP-3RT engages three by adding glucagon-receptor (GCGR) activity. Both are studied in vitro for incretin receptor binding and downstream cAMP signaling.